U.S. Department of Health & Human Services Divider Arrow National Institutes of Health Divider Arrow NCATS

Details

Stereochemistry ABSOLUTE
Molecular Formula C36H53N7O6
Molecular Weight 679.8493
Optical Activity UNSPECIFIED
Defined Stereocenters 6 / 6
E/Z Centers 0
Charge 0

SHOW SMILES / InChI
Structure of TELAPREVIR

SMILES

[H][C@@]12CCC[C@]1([H])[C@H](N(C2)C(=O)[C@@H](NC(=O)[C@@H](NC(=O)C3=CN=CC=N3)C4CCCCC4)C(C)(C)C)C(=O)N[C@@H](CCC)C(=O)C(=O)NC5CC5

InChI

InChIKey=BBAWEDCPNXPBQM-GDEBMMAJSA-N
InChI=1S/C36H53N7O6/c1-5-10-25(29(44)34(48)39-23-15-16-23)40-33(47)28-24-14-9-13-22(24)20-43(28)35(49)30(36(2,3)4)42-32(46)27(21-11-7-6-8-12-21)41-31(45)26-19-37-17-18-38-26/h17-19,21-25,27-28,30H,5-16,20H2,1-4H3,(H,39,48)(H,40,47)(H,41,45)(H,42,46)/t22-,24-,25-,27-,28-,30+/m0/s1

HIDE SMILES / InChI

Description
Curator's Comment: description was created based on several sources, including http://www.millionpharma.com/telaprevir.php; https://www.jnj.com/media-center/press-releases/incivo-telaprevir-approved-in-europe-offering-higher-cure-rates-for-genotype-1-chronic-hepatitis-c-compared-to-standard-treatment

Telaprevir (marketed under the brand names Incivek and Incivo) is a direct-acting antiviralagent against the hepatitis C virus (HCV). It is a hepatitis C virus NS3/4A protease inhibitor indicated for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers in combination with peginterferon alfa and ribavirin. Telaprevir is not used as a monotherapy. It is necessary for the proteolytic cleavage of the HCV encoded polyprotein into mature forms of the NS4A, NS4B, NS5A and NS5B proteins and essential for viral replication. It belongs to the chemical class of alpha-ketoamids and binds to NS3/4A in a covalent but reversible manner.

Originator

Curator's Comment: The Janssen Companies have the right to commercialize telaprevir in Europe, Latin America, the Middle East, Africa, India, Australia and New Zealand under the commercial name INCIVO®; Vertex has the right to commercialize telaprevir in North America under the name INCIVEK™ (approved by US FDA in May 2011 and by Health Canada in August 2011 for genotype-1 chronic hepatitis C with compensated liver disease); Mitsubishi Tanabe Pharma has the right to commercialize telaprevir in Japan and certain Far Eastern countries. # Tibotec (Janssen Pharmaceutical Companies) in collaboration with Vertex and Mitsubishi Tanabe Pharma

Approval Year

Targets

Targets

Primary TargetPharmacologyConditionPotency
10.0 nM [IC50]
Conditions

Conditions

ConditionModalityTargetsHighest PhaseProduct
Curative
INCIVEK

Approved Use

Indicated, in combination with peginterferon alfa and ribavirin, for the treatment of genotype 1 chronic hepatitis C (CHC) in adult patients with compensated liver disease, including cirrhosis, who are treatment-naïve or who have been previously treated with interferon-based treatment, including prior null responders, partial responders, and relapsers. Incivek must not be used as monotherapy and must only be used in combination with peginterferon alfa and ribavirin.

Launch Date

1.30610876E12
Cmax

Cmax

ValueDoseCo-administeredAnalytePopulation
1940 ng/mL
750 mg 3 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VRT-127394 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
511 ng/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VRT-127394 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3090 ng/mL
750 mg 3 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
1740.84 ng/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3232.22 ng/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
539.79 ng/mL
375 mg single, oral
dose: 375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
AUC

AUC

ValueDoseCo-administeredAnalytePopulation
13274.77 ng × h/mL
750 mg 3 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
VRT-127394 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
5203 ng × h/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VRT-127394 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
19809.27 ng × h/mL
750 mg 3 times / day steady-state, oral
dose: 750 mg
route of administration: Oral
experiment type: STEADY-STATE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: UNKNOWN
11749.1 ng × h/mL
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
24250.23 ng × h/mL
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3146.52 ng × h/mL
375 mg single, oral
dose: 375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
T1/2

T1/2

ValueDoseCo-administeredAnalytePopulation
4.77 h
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
VRT-127394 plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3.96 h
750 mg single, oral
dose: 750 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
6.49 h
1500 mg single, oral
dose: 1500 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
3.23 h
375 mg single, oral
dose: 375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Funbound

Funbound

ValueDoseCo-administeredAnalytePopulation
32.5%
375 mg single, oral
dose: 375 mg
route of administration: Oral
experiment type: SINGLE
co-administered:
TELAPREVIR plasma
Homo sapiens
population: HEALTHY
age: ADULT
sex: UNKNOWN
food status: FED
Doses

Doses

DosePopulationAdverse events​
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: chronic hepatitis C virus
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Disc. AE: DRESS syndrome...
AEs leading to
discontinuation/dose reduction:
DRESS syndrome (1 patient)
Sources:
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Other AEs: Nausea, Headache...
Other AEs:
Nausea
Headache
Diarrhea
Decreased appetite
Dysgeusia
Vomiting
Sources:
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources: Page: p. 68
unhealthy, adult
n = 1797
Health Status: unhealthy
Age Group: adult
Population Size: 1797
Sources: Page: p. 68
Disc. AE: Anemia, Skin disorder...
AEs leading to
discontinuation/dose reduction:
Anemia (22%)
Skin disorder (20%)
Fatigue (6%)
Nausea (4%)
Vomiting (4%)
Sources: Page: p. 68
AEs

AEs

AESignificanceDosePopulation
DRESS syndrome 1 patient
Disc. AE
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources:
unhealthy, 58 years
n = 1
Health Status: unhealthy
Condition: chronic hepatitis C virus
Age Group: 58 years
Sex: F
Population Size: 1
Sources:
Decreased appetite
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Diarrhea
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Dysgeusia
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Headache
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Nausea
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Vomiting
1875 mg 3 times / day multiple, oral
Highest studied dose
Dose: 1875 mg, 3 times / day
Route: oral
Route: multiple
Dose: 1875 mg, 3 times / day
Sources:
healthy, adult
Skin disorder 20%
Disc. AE
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources: Page: p. 68
unhealthy, adult
n = 1797
Health Status: unhealthy
Age Group: adult
Population Size: 1797
Sources: Page: p. 68
Anemia 22%
Disc. AE
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources: Page: p. 68
unhealthy, adult
n = 1797
Health Status: unhealthy
Age Group: adult
Population Size: 1797
Sources: Page: p. 68
Nausea 4%
Disc. AE
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources: Page: p. 68
unhealthy, adult
n = 1797
Health Status: unhealthy
Age Group: adult
Population Size: 1797
Sources: Page: p. 68
Vomiting 4%
Disc. AE
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources: Page: p. 68
unhealthy, adult
n = 1797
Health Status: unhealthy
Age Group: adult
Population Size: 1797
Sources: Page: p. 68
Fatigue 6%
Disc. AE
750 mg 3 times / day multiple, oral
Recommended
Dose: 750 mg, 3 times / day
Route: oral
Route: multiple
Dose: 750 mg, 3 times / day
Co-administed with::
peginterferon alfa
ribavirin
Sources: Page: p. 68
unhealthy, adult
n = 1797
Health Status: unhealthy
Age Group: adult
Population Size: 1797
Sources: Page: p. 68
OverviewDrug as perpetrator​

Drug as perpetrator​

TargetModalityActivityMetaboliteClinical evidence
likely
no
no
yes (co-administration study)
Comment: telaprevir caused a nearly 2-fold increase in exposure (Cmax, AUClast) to digoxin. Clearance of digoxin was decreased by 46% in the presence of telaprevir
Page: 50.0
unlikely
unlikely
unlikely
weak [IC50 >100 uM]
weak [IC50 >100 uM]
weak [IC50 >100 uM]
weak [IC50 >100 uM]
weak [IC50 >100 uM]
weak [IC50 >100 uM]
weak [IC50 >100 uM]
weak [IC50 >100 uM]
yes [IC50 2.8 uM]
weak (co-administration study)
Comment: 21 days of dosing with Modicon (0.5 mg NE + 0.035 mg EE) and telaprevir resulted in a decrease in EE plasma concentrations: Mean EE Cmax, Cmin, and AUCss were decreased by 26%, 32%, and 27%, respectively. Telaprevir also decreased NE exposure: mean NE Cmax, Cmin, and AUCss were decreased by 16%, 7%, and 10%, respectively
Page: 81.0
Drug as victim

Drug as victim

TargetModalityActivityMetaboliteClinical evidence
major
yes (co-administration study)
Comment: mean telaprevir AUCinf and mean AUC0-24h values were approximately 67% higher and mean telaprevir Cmax values were approximately 29% higher in subjects receiving telaprevir+ketoconazole; rifampin causes a significant increase in CYP3A4 metabolism resulting in a greater than 10-fold decrease in telaprevir AUClast exposure and 7-fold decrease in Cmax; Lopinavir/ritonavir (CYP3A4/P-gp inhibitors) significantly lowers telaprevir exposure (54% decrease in AUCτ and 55% decrease in Cmax) and could result in subtherapeutic concentrations of telaprevir
Page: 48.0
no
no
no
no
no
yes
yes (co-administration study)
Comment: Lopinavir/ritonavir (CYP3A4/P-gp inhibitors) significantly lowers telaprevir exposure (54% decrease in AUCτ and 55% decrease in Cmax) and could result in subtherapeutic concentrations of telaprevir
Page: 49.0
Tox targets

Tox targets

TargetModalityActivityMetaboliteClinical evidence
PubMed

PubMed

TitleDatePubMed
Synthesis of potent antitumor and antiviral benzofuran derivatives.
2009 May 1
A cell protection screen reveals potent inhibitors of multiple stages of the hepatitis C virus life cycle.
2010 Feb 23
Improved P2 phenylglycine-based hepatitis C virus NS3 protease inhibitors with alkenylic prime-side substituents.
2010 Jul 15
Preclinical characterization of BI 201335, a C-terminal carboxylic acid inhibitor of the hepatitis C virus NS3-NS4A protease.
2010 Nov
Telaprevir: pharmacokinetics and drug interactions.
2012
Azetidines and spiro azetidines as novel P2 units in hepatitis C virus NS3 protease inhibitors.
2013 Dec 1
Inhibition of hepatitis C virus replication by GS-6620, a potent C-nucleoside monophosphate prodrug.
2014
Hepatitis C virus: Virology, diagnosis and treatment.
2015 Jun 8
Patents

Sample Use Guides

1125 mg taken twice daily (10-14 hours apart) with food (not low fat). Incivek must be administered with both peginterferon alfa and ribavirin for all patients for 12 weeks, followed by a response-guided regimen of either 12 or 36 additional weeks of peginterferon alfa and ribavirin depending on viral response and prior response status.
Route of Administration: Oral
Telaprevir demonstrated excellent antiviral activity both in genotype 1b HCV replicon cells with the IC50 of 354 nM and in human fetal hepatocytes infected with genotype 1a HCV-positive patient sera (IC50 = 280 nM).
Name Type Language
TELAPREVIR
DASH   INN   JAN   MART.   MI   ORANGE BOOK   USAN   VANDF   WHO-DD  
USAN   INN  
Official Name English
Telaprevir [WHO-DD]
Common Name English
VRT-111950
Code English
VX-950
Code English
TELAPREVIR [JAN]
Common Name English
LY 570310
Code English
INCIVO
Brand Name English
VRT 111950
Code English
telaprevir [INN]
Common Name English
(1S,3aR,6aS)-2-[(2S)-2-[[(2S)-Cyclohexyl[(pyrazinylcarbonyl)amino]acetyl]amino]-3,3-dimethylbutanoyl]-N-[(1S)-1-[(cyclopropylamino)oxoacetyl]butyl] octahydrocyclopenta[c]pyrrole-1-carboxamide
Common Name English
TELAPREVIR [ORANGE BOOK]
Common Name English
TELAPREVIR [USAN]
Common Name English
LY-570310
Code English
MP 424
Code English
INCIVEK
Brand Name English
TELAPREVIR [VANDF]
Common Name English
CYCLOPENTA(C)PYRROLE-1-CARBOXAMIDE, (2S)-2-CYCLOHEXYL-N-(PYRAZINYLCARBONYL)GLYCYL-3-METHYL-L-VALYL-N-((1S)-1-((CYCLOPROPYLAMINO)OXOACETYL)BUTYL)OCTAHYDRO-, (1S,3AR,6AS)-
Common Name English
VX 950
Code English
MP-424
Code English
TELAPREVIR [MI]
Common Name English
TELAPREVIR [MART.]
Common Name English
Classification Tree Code System Code
WHO-VATC QJ05AE11
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
EMA ASSESSMENT REPORTS INCIVO (AUTHORIZED: HEPATITIS C, CHRONIC)
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
NDF-RT N0000182639
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
NCI_THESAURUS C783
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
LIVERTOX NBK548138
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
NCI_THESAURUS C281
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
WHO-ATC J05AP02
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
WHO-ATC J05AE11
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
Code System Code Type Description
FDA UNII
655M5O3W0U
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
HSDB
8125
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
USAN
SS-135
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
CAS
402957-28-2
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
MESH
C486464
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
NDF-RT
N0000190114
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY Cytochrome P450 3A Inhibitors [MoA]
NDF-RT
N0000190109
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY Organic Anion Transporting Polypeptide 2B1 Inhibitors [MoA]
EVMPD
SUB31651
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
NDF-RT
N0000182638
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY HCV NS3/4A Protease Inhibitors [MoA]
DRUG BANK
DB05521
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
DRUG CENTRAL
4173
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
INN
8686
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
NCI_THESAURUS
C81603
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
EPA CompTox
DTXSID40193304
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
PUBCHEM
3010818
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
CHEBI
68595
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
LACTMED
Telaprevir
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
SMS_ID
100000124179
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
RXCUI
1102261
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY RxNorm
NDF-RT
N0000185503
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY P-Glycoprotein Inhibitors [MoA]
NDF-RT
N0000190107
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY Organic Anion Transporting Polypeptide 1B1 Inhibitors [MoA]
MERCK INDEX
m10526
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY Merck Index
ChEMBL
CHEMBL231813
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY
WIKIPEDIA
TELAPREVIR
Created by admin on Fri Dec 15 16:04:26 UTC 2023 , Edited by admin on Fri Dec 15 16:04:26 UTC 2023
PRIMARY